Top

Published in:

01-01-2017 | Laboratory Investigation

Clinical and prognostic role of annexin A2 in adamantinomatous craniopharyngioma

Authors: Yuelong Wang, Jiaojiao Deng, Gang Guo, Aiping Tong, Xirui Peng, Haifeng Chen, Jianguo Xu, Yi Liu, Chao You, Liangxue Zhou

Published in: Journal of Neuro-Oncology | Issue 1/2017

Abstract

Annexin A2 (AnxA2) is a highly conserved Ca2⁺-regulated membrane binding protein, which affects cell mobility and tumor progression. Adamantinomatous craniopharyngioma (AdaCP) are a kind of epithelial tumors of the sellar region with high tendency to recur. Robust biomarkers are required to predict tumor behavior and to establish follow-up individualized treatment approaches. In this study, we firstly compared four surgical AdaCP samples with normal brain by two-dimensional gel electrophoresis (2DE) proteomic analysis. Potential prognostic biomarkers were further validated in a large cohort of 65 AdaCPs by immunohistochemistry. The effects of AnxA2 on AdaCP cells proliferation and migration were analyzed in vitro with isolated primary AdaCP cells as well as SV40T-immortalized cells. Finally, the gefitinib sensitivity of AdaCPs with differentially expressed AnxA2 and the potential molecular mechanisms were examined by flow cytometric analysis, Real-time PCR and immunoblot assays. Proteomic analysis indicated that AnxA2 was the protein spot with the most elevated expression in AdaCP samples. Immunohistochemistry assays indicated the expression level of AnxA2 was significantly higher in recurrent AdaCPs compared with primary ones. Moreover, AnxA2⁺ AdaCP cells exhibited enhanced proliferation and migration ability compared with AnxA2⁻ AdaCP cells in vitro. Further, we show that AnxA2⁺ AdaCP cells exhibited elevated expression of EGFR and downstream p-AKT (S308) and p-AKT (S473), and were more sensitive to tyrosine kinase inhibitor gefitinib. Our data suggest that AnxA2 may serve as a promising biomarker for AdaCP progression, recurrence and drug susceptibility. Our data support potential clinical implications for the follow-up treatment of AdaCP patients with high AnxA2 expression.

Available only for authorised users

Brastianos PK et al (2014) Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet 46:161–165. doi:10.1038/ng.2868 CrossRefPubMedPubMedCentral

Kim JH, Paulus W, Heim S (2015) BRAF V600E mutation is a useful marker for differentiating Rathke’s cleft cyst with squamous metaplasia from papillary craniopharyngioma. J Neurooncol 123:189–191. doi:10.1007/s11060-015-1757-6 CrossRefPubMed

Réty S et al (1999) The crystal structure of a complex of p11 with the annexin II N-terminal peptide. Nat Struct Biol 6(1):89–95CrossRefPubMed

Hayes MJ et al (2004) Annexin-actin interactions. Traffic 5:571–576. doi:10.1111/j.1600-0854.2004.00210.x CrossRefPubMed

Emoto K et al (2007) Annexin II overexpression correlates with stromal tenascin-C overexpression: a prognostic marker in colorectal carcinoma. Cancer 92:1419–1426. doi:10.1002/1097-0142(20010915)92:6<1419::AID-CNCR1465>3.0.CO;2-J CrossRef

Singh P et al (2007) Annexin II binds progastrin and gastrin-like peptides, and mediates growth factor effects of autocrine and exogenous gastrins on colon cancer and intestinal epithelial cells. Oncogene 26:425–440. doi:10.1038/sj.onc.1209798 CrossRefPubMed

Sharma MR et al (2006) Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression. Exp Mol Pathol 81:146–156. doi:10.1016/j.yexmp.2006.03.003 CrossRefPubMed

Bao H et al (2009) Overexpression of annexinii affects the proliferation, apoptosis, invasion and production of proangiogenic factors in multiple myeloma. Int J Hematol 90:177–185. doi:10.1007/s12185-009-0356-8 CrossRefPubMed

Qingxiang S et al (2016) Inhibiting cancer cell hallmark features through nuclear export inhibition. Signal Transduct Target Ther 1:16010. doi:10.1038/sigtrans.2016.10

10.

Zhai H et al (2011) Annexin A2 promotes glioma cell invasion and tumor progression. J Neurosci 31:14346–14360. doi:10.1523/JNEUROSCI.3299-11.2011 CrossRefPubMedPubMedCentral

11.

Jia JW et al (2013) Clinical significance of annexin II expression in human non-small cell lung cancer. Tumour Biol 34:1767–1771. doi:10.1007/s13277-013-0715-1 CrossRefPubMed

12.

Emoto K et al (2001) Annexin II overexpression is correlated with poor prognosis in human gastric carcinoma. Anticancer Res 21:1339–1345PubMed

13.

Roseman BJ et al (1994) Annexin II marks astrocytic brain tumors of high histologic grade. Oncol Res 6:561–567PubMed

14.

Diaz VM et al (2004) Specific interaction of tissue-type plasminogen activator (t-PA) with annexin II on the membrane of pancreatic cancer cells activates plasminogen and promotes invasion in vitro. Gut 53:993–1000. doi:10.1136/gut.2003.026831 CrossRefPubMedPubMedCentral

15.

Sharma M et al (2011) Antibody-directed neutralization of annexin II (ANX II) inhibits neoangiogenesis and human breast tumor growth in a xenograft model. Exp Mol Pathol 92:175–184. doi:10.1016/j.yexmp.2011.10.003 CrossRefPubMed

16.

Alonso-Alconada L et al (2015) Annexin-A2 as predictor biomarker of recurrent disease in endometrial cancer. Int J Cancer 136:1863–1873. doi:10.1002/ijc.29213 CrossRefPubMed

17.

Shi XE, Wu B, Fan T et al (2008) Craniopharyngioma: surgical experience of 309 cases in China. Clin Neurol Neurosurg 110(2):151–159CrossRefPubMed

18.

Van Effenterre R, Boch AL (2002) Craniopharyngioma in adults and children: a study of 122 surgical cases. J Neurosurg 97:3–11CrossRefPubMed

19.

Kapustin AN et al (2011) Calcium regulates key components of vascular smooth muscle cell–derived matrix vesicles to enhance mineralization. Circ Res 109:E1–E41. doi:10.1161/CIRCRESAHA.110.238808 CrossRefPubMed

20.

Balcerzak M et al (2003) The roles of annexins and alkaline phosphatase in mineralization process. Biochim Pol 50:1019–1038

21.

Ali SH, DeCaprio JA (2001) Cellular transformation by SV40 large T antigen: interaction with host proteins. Semin Cancer Biol 11:15–23. doi:10.1006/scbi.2000.0342 CrossRefPubMed

22.

Kurosaki M et al (2001) Immunohistochemical localisation of cytokeratins in craniopharyngioma. Acta Neurochir 143:147–151CrossRefPubMed

23.

Rankin CR et al (2013) Annexin A2 regulates beta1 integrin internalization and intestinal epithelial cell migration. J Biol Chem 288:15229–15239. doi:10.1074/jbc.M112.440909 CrossRefPubMedPubMedCentral

24.

Sharma MC, Sharma M (2007) The role of annexin II in angiogenesis and tumor progression: a potential therapeutic target. Curr Pharm Des 13:3568–3575. doi:10.2174/138161207782794167 CrossRefPubMed

25.

Chuthapisith S et al (2009) Annexins in human breast cancer: possible predictors of pathological response to neoadjuvant chemotherapy. Eur J Cancer 45:1274–1281. doi:10.1016/j.ejca.2008.12.026 CrossRefPubMed

26.

Braden AR et al (2009) Polymeric nanoparticles for sustained down-regulation of annexin A2 inhibit prostate tumor growth. J Nanosci Nanotechnol 9:2856–2865. doi:10.1166/jnn.2009.028 CrossRefPubMed

27.

Huang Y et al (2008) Involvement of annexin A2 in p53 induced apoptosis in lung cancer. Mol Cell Biochem 309:117–123. doi:10.1007/s11010-007-9649-5 CrossRefPubMed

28.

Creutz CE, Snyder SL (2005) Interactions of annexins with the mu subunits of the clathrin assembly proteins. BioChemistry 44:13795–13806. doi:10.1021/bi051160w CrossRefPubMed

29.

Grewal T, Enrich C (2009) Annexins-modulators of EGF receptor signalling and trafficking. Cell Signal 21:847–858. doi:10.1016/j.cellsig.2009.01.031 CrossRefPubMed

30.

Kharait S et al (2006) Protein kinase Cdelta signaling downstream of the EGF receptor mediates migration and invasiveness of prostate cancer cells. Biochem Biophys Res Commun 343:848–856. doi:10.1016/j.bbre.2006.03.044 CrossRefPubMed

31.

Sebolt-Leopold JS, Herrera R (2004) Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4:937–947. doi:10.1038/nrc1503 CrossRefPubMed

32.

Hölsken A et al (2011) EGFR signaling regulates tumor cell migration in craniopharyngiomas. Clin Cancer Res 17:4367–4377. doi:10.1158/1078-0432.CCR-10-2811 CrossRefPubMed

33.

Jung H et al (2015) Intracellular annexin A2 regulates NF-κB signaling by binding to the p50 subunit: implications for gemcitabine resistance in pancreatic cancer. Cell Death Dis 6:e1606. doi:10.1038/cddis.2014.558 CrossRefPubMedPubMedCentral

34.

Spijkers-Hagelstein JA et al (2013) Src kinase-induced phosphorylation of annexin A2 mediates glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia. Leukemia 27:1063–1071. doi:10.1038/leu.2012.372 CrossRefPubMed

Title: Clinical and prognostic role of annexin A2 in adamantinomatous craniopharyngioma
Authors: Yuelong Wang
Jiaojiao Deng
Gang Guo
Aiping Tong
Xirui Peng
Haifeng Chen
Jianguo Xu
Yi Liu
Chao You
Liangxue Zhou
Publication date: 01-01-2017
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 1/2017
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-016-2273-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Clinical and prognostic role of annexin A2 in adamantinomatous craniopharyngioma

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2017

Novel insights into vascularization patterns and angiogenic factors in glioblastoma subclasses

Characterization of the distribution, retention, and efficacy of internal radiation of 188Re-lipid nanocapsules in an immunocompromised human glioblastoma model

Influence of glioblastoma contact with the lateral ventricle on survival: a meta-analysis

Incidence, time trends and survival patterns of childhood pilocytic astrocytomas in Southern-Eastern Europe and SEER, US

Toxicity profile of bevacizumab in the UK Neurofibromatosis type 2 cohort

Preliminary experience of the concurrent use of radiosurgery and T-DM1 for brain metastases in HER2-positive metastatic breast cancer